Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.59 |
| ▸ | HTR6 | P50406 | 10/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3B | O95264 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4171025 | 0.98 | ADRB1 (0.57) | ADRB1HTR6SIGMAR1DRD2DRD1 | |
| SCHEMBL31051992 | 0.83 | HTR1A (0.50) | ADRB1DRD2HTR1ACYP3A4CYP2C9 | |
| SCHEMBL31051799 | 0.81 | HTR1A (0.52) | ADRB1DRD2DRD1HTR2ADRD3 | |
| SCHEMBL31052148 | 0.81 | HTR1A (0.52) | ADRB1DRD2DRD1HTR2ADRD3 | |
| SCHEMBL16703491 | 0.81 | ADRB1 (0.59) | ADRB1HTR6SIGMAR1DRD2DRD1 | |
| SCHEMBL7815929 | 0.81 | ADRB1 (0.59) | ADRB1HTR6SIGMAR1DRD2DRD1 | |
| SCHEMBL7808439 | 0.81 | ADRB1 (0.59) | ADRB1HTR6SIGMAR1DRD2DRD1 | |
| SCHEMBL31051842 | 0.81 | ADRB1 (0.59) | ADRB1HTR6SIGMAR1DRD2DRD1 | |
| SCHEMBL31051835 | 0.81 | ADRB1 (0.59) | ADRB1HTR6SIGMAR1DRD2DRD1 | |
| SCHEMBL31051921 | 0.81 | ADRB1 (0.59) | ADRB1HTR6SIGMAR1DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678188-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | Ohnishi, Arata (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024185842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING, OR MANAGING BILIRUBIN-INDUCED NEUROLOGICAL DYSFUNCTION, PSYCHIATRIC DISORDERS ASSOCIATED WITH JAUNDICE, OR PSYCHIATRIC DISORDERS CAUSED BY BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE GENE MUTATIONS | 国立大学法人島根大学 | 2024-09-12 | — | — | WO | disclosed |
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |
| US-7910591-B2 | e.g. 3-[4-(4-Pyridine-2-yl-piperazine-1-yl)-butyl]-1,3-dihydro-2H-indol-2-one; serotonin 5-HT7 and alpha 1 receptors modulator; antxiolytic agent, antidepressant; neurodegenerative diseases; schizophrenia, Alzheimer's disease, stroke, dementias; side effect reduction | EGIS GYOGYSZERGYAR NYRT. (HU) | 2011-03-22 | — | — | US | disclosed |
| WO-2008146064-A1 | NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT7 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION | EGIS GYÓGYSZERGYÁR (HU) | 2008-12-04 | — | — | WO | disclosed |
| EP-1751105-B1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYOGYSZERGYAR NYRT (HU) | 2008-10-29 | — | — | EP | disclosed |
| US-20080161323-A1 | Piperazine Derivatives of Alkyl Oxindoles | EGIS GYOGYSZERGYAR RT. (HU) | 2008-07-03 | — | — | US | disclosed |
| EP-1751105-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040242873-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | EGIS GYOGYSZERGYAR RT. (HU) | 2004-12-02 | — | — | US | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| EP-1430047-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Egis Gyogyszergyar Rt. (HU) | 2004-06-23 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003027097-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGIS Gyógyszergyár Rt. (HU) | 2003-04-03 | — | — | WO | disclosed |
| EP-0633260-B1 | 2,3-Dihydro-1,4-benzodioxan-5-yl-piperazine derivatives having 5-HT1A-antagonistic activity | DUPHAR INT RES (NL) | 2001-11-07 | — | — | EP | disclosed |
| US-5462942-A | 2,3-dihydro-1,4-benzodioxin-5-yl-piperazine derivatives having 5-HT 1A-antagonistic activity | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1995-10-31 | — | — | US | disclosed |
| EP-0633260-A1 | 2,3-Dihydro-1,4-benzodioxin-5-yl-piperazine derivatives having 5-HT1A-antagonistic activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1995-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | ADRB1 28/4885HTR6 38/4885SIGMAR1 117/4885 |
| US-20040242873-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | CYP3A5, CYP11B1, ADRA1D | ADRB1 11/4885HTR6 82/4885SIGMAR1 68/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | ADRB1 28/4885HTR6 20/4885SIGMAR1 195/4885 |
| US-20080161323-A1 | Piperazine Derivatives of Alkyl Oxindoles | TPH2, CNR2, HTR5A | ADRB1 86/4885HTR6 32/4885SIGMAR1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.